All Systems Go For Novartis 'World-First' Leqvio Pact With England
As NICE Recommends Twice-Yearly Cholesterol Drug
A price has finally been agreed for Novartis's small interfering RNA therapy and over the next three years, NHS England now expects to treat about 300,000 patients at high risk of a second cardiovascular event with inclisiran.
